VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Molecular Profiling in Colorectal Cancer

Panelists: Axel F. Grothey, MD , Mayo Clinic ; Daniel G. Haller, MD, University of Pennsylvania; Herbert I. Hurwitz, MD, Duke University Medical Center; J
Published: Wednesday, Jun 03, 2015

For High-Definition, Click
The panel members agree that the majority of molecular tests, aside from those looking at microsatellite instability and RAS or RAF mutations, are not ready for primetime for patients with colorectal cancer (CRC). Right now, explains John P. Marshall, MD, 17-page reports with 150 references cataloguing a patients’ mutations are being generated. However, this information comes without evidence-based knowledge of what to do with it.
 
It's hoped that in 5 to 10 years that there will be standard genetic markers to use longitudinally, for example with circulating tumor cells, to help guide  treatment decisions, notes Axel Grothey, MD However, at this time actionable alterations are in short supply in CRC. The danger of acting on the information from pan-molecular testing is uncontrolled use of drugs without capturing information about the outcomes, Grothey adds.
Slider Left
Slider Right

For High-Definition, Click
The panel members agree that the majority of molecular tests, aside from those looking at microsatellite instability and RAS or RAF mutations, are not ready for primetime for patients with colorectal cancer (CRC). Right now, explains John P. Marshall, MD, 17-page reports with 150 references cataloguing a patients’ mutations are being generated. However, this information comes without evidence-based knowledge of what to do with it.
 
It's hoped that in 5 to 10 years that there will be standard genetic markers to use longitudinally, for example with circulating tumor cells, to help guide  treatment decisions, notes Axel Grothey, MD However, at this time actionable alterations are in short supply in CRC. The danger of acting on the information from pan-molecular testing is uncontrolled use of drugs without capturing information about the outcomes, Grothey adds.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x